Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Pfizer launches mRNA-based influenza vaccine trial

by French Press Agency - AFP

Washington Sep 28, 2021 - 9:53 am GMT+3
 A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., Dec. 7, 2020. (Reuters Photo)
A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., Dec. 7, 2020. (Reuters Photo)
by French Press Agency - AFP Sep 28, 2021 9:53 am
RECOMMENDED
Snow geese take off from a field in Ruthsburg, Maryland, U.S., Jan. 25, 2023. (AFP Photo)

Concerning bird flu spreads through mammals but low risk to humans

health

Following the success of COVID-19 shots designed with mRNA technology, the U.S. pharmaceutical company Pfizer said Monday it started a clinical trial to test an influenza vaccine produced with the same technology.

The idea is to improve on the current generation of flu vaccines that have an efficacy of 40-60% against a disease that can cause up to 650,000 deaths a year.

"The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA," Kathrin Jansen, head of vaccine research at Pfizer, said in a statement.

"Influenza remains an area where we see a need for vaccines, which could result in improved efficacy in any given season, and we believe mRNA is the ideal technology to take on this challenge."

The early stage study will recruit more than 600 Americans aged 65 to 85, according to a company statement and a government website listing the trial.

Specifically, Pfizer wants to compare the safety and level of immune response of a single, double and quadruple strain mRNA vaccine at different dosage levels versus a conventional, licensed quadruple strain vaccine.

Conventional seasonal flu vaccines are generally cultured by growing the virus inside chicken eggs or mammalian cells.

The viruses are inactivated and processed to be turned into vaccines.

The process is fraught with challenges, including producing vaccines that evoke a strong response and keeping up with virus strain changes.

Experts have to predict the best match for next season's vaccine six months out.

The promise of mRNA (messenger ribonucleic) acid technology is that they only require the genetic sequence of the virus, or a specific part of it, enabling faster and more flexible production.

The human body reads the genetic code and produces virus-like cells that train the immune system to be prepared for the real thing.

Pfizer began work on its mRNA influenza vaccine in 2018 with its German partner BioNTech, which would receive a royalty upon approval and commercialization.

In the future, Pfizer plans to explore mRNA medicine against other respiratory viruses, cancer and genetic diseases.

Moderna likewise is working on an mRNA flu vaccine and one against the respiratory syncytial virus (RSV).

RECOMMENDED
Snow geese take off from a field in Ruthsburg, Maryland, U.S., Jan. 25, 2023. (AFP Photo)

Concerning bird flu spreads through mammals but low risk to humans

health
  • shortlink copied
  • Last Update: Sep 28, 2021 10:58 am
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    vaccine research influenza vaccine pfizer flu vaccine
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    The NATO flag waves during the Canadian-led NATO Enhanced Forward Presence (eFP) Battlegroup Latvia fifth anniversary event at the Adazi Military Base in Latvia, June 15, 2022. (EPA Photo)

    NATO allies mobilize support after Türkiye earthquake: Stoltenberg

    türkiye-earthquake
    A man looks on at search and rescue operations conducted in the rubble of a collapsed building, in Diyarbakır, Türkiye, Feb. 6, 2023. (AFP Photo)

    Erdoğan discusses earthquake situation with party leaders

    EARTHQUAKE

    Türkiye declares 7 days of national mourning after earthquakes

    türkiye

    Rescue teams depart across globe to assist Türkiye in quake-aftermath

    EARTHQUAKE
    No Image
    Türkiye's biggest aerospace, tech event Teknofest ends
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021